Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2000;31:2478-2486

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nishimura, Y.
Right arrow Articles by Sandberg, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nishimura, Y.
Right arrow Articles by Sandberg, K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Cerebrovascular disease/stroke
Right arrow Primary prevention
Right arrow ACE/Angiotension receptors
Right arrow Acute Cerebral Infarction
Right arrow Brain Circulation and Metabolism

(Stroke. 2000;31:2478.)
© 2000 American Heart Association, Inc.


Original Contributions

Angiotensin II AT1 Blockade Normalizes Cerebrovascular Autoregulation and Reduces Cerebral Ischemia in Spontaneously Hypertensive Rats

Yasuaki Nishimura, MD, PhD; Takeshi Ito, MD Juan M. Saavedra, MD

From the Section on Pharmacology, Intramural Research Program, National Institute of Mental Health, Bethesda, Md.

Correspondence to Juan M. Saavedra, MD, Section on Pharmacology, Intramural Research Program, National Institute of Mental Health, 10 Center Dr, Bldg 10, Room 2D-57, Bethesda, MD 20892. E-mail Saavedrj{at}irp.nimh.nih.gov

Background and Purpose—Angiotensin II, through stimulation of AT1 receptors, not only controls blood pressure but also modulates cerebrovascular flow. We sought to determine whether selective AT1 antagonists could be therapeutically advantageous in brain ischemia during chronic hypertension.

Methods—We pretreated spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto controls with the AT1 antagonist candesartan (CV-11974), 0.5 mg/kg per day, for 3 to 14 days, via subcutaneously implanted osmotic minipumps. We analyzed cerebral blood flow by laser-Doppler flowmetry, cerebral stroke in SHR after occlusion of the middle cerebral artery with reperfusion, and brain AT1 receptors by quantitative autoradiography.

Results—Candesartan treatment normalized blood pressure and the shift toward higher blood pressures at both the upper and lower limits of cerebrovascular autoregulation in SHR. Candesartan pretreatment of SHR for 14 days partially prevented the decrease in blood flow in the marginal zone of ischemia and significantly reduced the volume of total and cortical infarcts after either 1 or 2 hours of middle cerebral artery occlusion with reperfusion, relative to untreated SHR, respectively. This treatment also significantly reduced brain edema after 2 hours of middle cerebral artery occlusion with reperfusion. In SHR, candesartan markedly decreased AT1 binding in areas inside (nucleus of the solitary tract) and outside (area postrema) the blood-brain barrier and in the middle cerebral artery.

Conclusions—Pretreatment with an AT1 antagonist protected hypertensive rats from brain ischemia by normalizing the cerebral blood flow response, probably through AT1 receptor blockade in cerebral vessels and in brain areas controlling cerebrovascular flow during stroke.

Editorial Comment

Kathryn Sandberg, Guest Editor

Center for Hypertension and Renal Disease Georgetown University Washington, DC




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
W. Kozak, A. Kozak, M. H. Johnson, H. F. Elewa, and S. C. Fagan
Vascular Protection with Candesartan after Experimental Acute Stroke in Hypertensive Rats: A Dose-Response Study
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 773 - 782.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
B. K. Saxby, F. Harrington, K. A. Wesnes, I. G. McKeith, and G. A. Ford
Candesartan and cognitive decline in older patients with hypertension: A substudy of the SCOPE trial
Neurology, May 6, 2008; 70(19_Part_2): 1858 - 1866.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
G. C. Newman, H. Bang, S. I. Hussain, and J. F. Toole
Association of diabetes, homocysteine, and HDL with cognition and disability after stroke
Neurology, November 27, 2007; 69(22): 2054 - 2062.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K.-H. Jung, K. Chu, S.-T. Lee, S.-J. Kim, E.-C. Song, E.-H. Kim, D.-K. Park, D.-I. Sinn, J.-M. Kim, M. Kim, et al.
Blockade of AT1 Receptor Reduces Apoptosis, Inflammation, and Oxidative Stress in Normotensive Rats with Intracerebral Hemorrhage
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1051 - 1058.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. H. Messerli
Cerebroprotection by Hypertension in Ischemic Stroke: The Crumbling of a Hypothesis
Circulation, June 12, 2007; 115(23): 2907 - 2908.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Ishikawa, E. Sekizuka, N. Yamaguchi, H. Nakadate, S. Terao, D. N. Granger, and H. Minamitani
Angiotensin II type 1 receptor signaling contributes to platelet-leukocyte-endothelial cell interactions in the cerebral microvasculature
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2306 - H2315.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. Paul, A. Poyan Mehr, and R. Kreutz
Physiology of local Renin-Angiotensin systems.
Physiol Rev, July 1, 2006; 86(3): 747 - 803.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Zhou, J. Pavel, M. Macova, Z.-X. Yu, H. Imboden, L. Ge, T. Nishioku, J. Dou, E. Delgiacco, and J. M. Saavedra
AT1 Receptor Blockade Regulates the Local Angiotensin II System in Cerebral Microvessels From Spontaneously Hypertensive Rats
Stroke, May 1, 2006; 37(5): 1271 - 1276.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J.-M. Vincent, Y. W. Kwan, S. Lung Chan, C. Perrin-Sarrado, J. Atkinson, and J.-M. Chillon
Constrictor and Dilator Effects of Angiotensin II on Cerebral Arterioles
Stroke, December 1, 2005; 36(12): 2691 - 2695.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Forder, D. H. Munzenmaier, and A. S. Greene
Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat
Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1989 - H1996.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
V. Papademetriou, C. Farsang, D. Elmfeldt, A. Hofman, H. Lithell, B. Olofsson, I. Skoog, P. Trenkwalder, A. Zanchetti, and for the SCOPE Study Group
Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The study on cognition and prognosis in the elderly (SCOPE)
J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1175 - 1180.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Iwai, H.-W. Liu, R. Chen, A. Ide, S. Okamoto, R. Hata, M. Sakanaka, T. Shiuchi, and M. Horiuchi
Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation
Circulation, August 17, 2004; 110(7): 843 - 848.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
S. I. Sokol, E. L. Portnay, J. P. Curtis, M. A. Nelson, P. R. Hebert, J. F. Setaro, and J. M. Foody
Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke
Neurology, July 27, 2004; 63(2): 208 - 213.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. Ando, J. Zhou, M. Macova, H. Imboden, and J. M. Saavedra
Angiotensin II AT1 Receptor Blockade Reverses Pathological Hypertrophy and Inflammation in Brain Microvessels of Spontaneously Hypertensive Rats
Stroke, July 1, 2004; 35(7): 1726 - 1731.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. Kusaka, G. Kusaka, C. Zhou, M. Ishikawa, A. Nanda, D. N. Granger, J. H. Zhang, and J. Tang
Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury
Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2442 - H2451.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
C. Delles, G. Michelson, J. Harazny, S. Oehmer, K. F. Hilgers, and R. E. Schmieder
Impaired Endothelial Function of the Retinal Vasculature in Hypertensive Patients
Stroke, June 1, 2004; 35(6): 1289 - 1293.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
E. Stenman and L. Edvinsson
Cerebral Ischemia Enhances Vascular Angiotensin AT1 Receptor-Mediated Contraction in Rats
Stroke, April 1, 2004; 35(4): 970 - 974.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
C. Bregonzio, I. Armando, H. Ando, M. Jezova, G. Baiardi, and J. M. Saavedra
Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury
Am J Physiol Gastrointest Liver Physiol, July 7, 2003; 285(2): G414 - G423.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. I. New, A. M. S. Chesser, R. C. Thuraisingham, and M. M. Yaqoob
Cerebral artery responses to pressure and flow in uremic hypertensive and spontaneously hypertensive rats
Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1212 - H1216.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
E. Tronvik, L. J. Stovner, G. Helde, T. Sand, and G. Bovim
Prophylactic Treatment of Migraine With an Angiotensin II Receptor Blocker: A Randomized Controlled Trial
JAMA, January 1, 2003; 289(1): 65 - 69.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. Ito, H. Yamakawa, C. Bregonzio, J. A. Terron, A. Falcon-Neri, and J. M. Saavedra
Protection Against Ischemia and Improvement of Cerebral Blood Flow in Genetically Hypertensive Rats by Chronic Pretreatment With an Angiotensin II AT1 Antagonist
Stroke, September 1, 2002; 33(9): 2297 - 2303.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
H. L Elliott and G. T McInnes
Special management needs of the elderly hypertensive patient
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1_suppl): S25 - S31.
[PDF]


Home page
FASEB J.Home page
T. WALTHER, L. OLAH, C. HARMS, B. MAUL, M. BADER, H. HORTNAGL, H.-P. SCHULTHEISS, and G. MIES
Ischemic injury in experimental stroke depends on angiotensin II
FASEB J, February 1, 2002; 16(2): 169 - 176.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
T. Ito, Y. Nishimura, and J. Saavedra
Pre-treatment with candesartan protects from cerebral ischaemia
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2001; 2(3): 174 - 179.
[Abstract] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
T. M Estrup, O. B Paulson, and S. Strandgaard
No effect of angiotensin II AT2-receptor antagonist PD 123319 on cerebral blood flow autoregulation
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2001; 2(3): 188 - 192.
[Abstract] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
J. Culman, J. Baulmann, A. Blume, and T. Unger
Review: The renin-angiotensin system in the brain: an update
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2001; 2(2): 96 - 102.
[PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
J. M Saavedra, T. Ito, and Y. Nishimura
Review: The role of angiotensin II AT1-receptors in the regulation of the cerebral blood flow and brain ischaemia
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S102 - S109.
[PDF]